Back

What have we learned? Long-term safety and efficacy of inclisiran

27 August 2023 (13:00 - 13:15)
Organised by: Logo
Congress Presentation Part of: Strategies to reach LDL-C goals in patients with high or very high CV risk: what's new for inclisiran? Lipid-Lowering Agents Open Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor R Scott Wright

Mayo Clinic, Rochester (United States of America)

3 More presentations in this session

Presentation thumbnail
Where are we now? Decision-making in LDL-C lowering and CV risk
Professor J. Jukema (Leiden, NL)
Slides Video
Presentation thumbnail
Where are we going? Population health and the VICTORION programme
Professor K. Ray (London, GB)
Slides Video
Presentation thumbnail
Q&A and meeting close
Professor J. Jukema (Leiden, NL) Professor K. Ray (London, GB) Professor R. Wright (Rochester, US)
Slides Video

Access the full session

Session thumbnail
Strategies to reach LDL-C goals in patients with high or very high CV risk: what's new for inclisiran?
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 13:00 CET
You may be interested in
thumbnail
Congress Session
Late-breaking science on pharmacology
28 August 2023
thumbnail
Congress Presentation
siRNA/Inclisiran and the CV continuum - are we reinventing LDL-C management?
30 August 2025
thumbnail
Congress Presentation
First clinical experiences with inclisiran in real world setting
28 August 2023
thumbnail
Congress Presentation
Value of sustained LDL-C lowering: learnings from long-term data
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources